reports
- Research Team ACF
NLS Pharmaceutics (NLSP) Core Investment Case 13022025
NLS Pharmaceutics (NLSP:NasdaqCM) is a clinical-stage Swiss foreign issuer biotech advancing the Dual Orexin Receptor Agonist (DOXA) platform, a next-generation approach to treating neurological, neurodegenerative (NDD), and metabolic disorders. The DOXA platform is designed to restore orexin signaling and modulate neuroinflammatory pathways, offering a possible market leading approach to sleep-wake disorders, ALS, and other NDDs. The DOXA platform presents a high-value opportunity for breakthro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.